By late 2026, TG Therapeutics was reporting higher revenue yet much lower net income than a year earlier, and even facing a law firm inquiry into potential governance issues. For TG Therapeutics shareholders, the return from the start of the year was 124.6%, including dividends. If you had been weighing a position back on 1 January, how should you have evaluated that eventual gain in light of the heavy dependence on BRIUMVI and the split between bullish and bearish analyst views?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
TG Therapeutics is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced.
The Two TG Therapeutics Stories Investors Were Choosing Between
The shares cost US$29.81 at the start of the period, and anyone looking at TG Therapeutics then had to choose between two sharply different stories.
On the optimistic side, the bullish Narrative saw a Fair Value of US$40.5, built on the assumption that revenue would rise by 39.5% a year and that profit margins could reach 38.1% by about 2028 as BRIUMVI expanded, including a planned subcutaneous launch.
The bearish Narrative pointed to a Fair Value of US$11, with concern that dependence on BRIUMVI left the business exposed to drug pricing scrutiny and patent pressure around 2029, even if earnings reached US$344.7 million only on a much lower assumed P/E of 6.7x.
What The 2026 Evidence Did To The TG Therapeutics Debate
For TG Therapeutics, the key development was BRIUMVI driven revenue of US$259.9 million in Q3 2026, up from US$161.7 million in Q3 2025, alongside higher full year revenue guidance tied to that product. Net income excluding extra items fell from US$390.9 million to US$55.5 million, so the profitability part of the bullish Narrative was not confirmed. Overall, the evidence cut both ways.
The big assumption was that BRIUMVI strength would translate into sustained earnings quality. When you look at another stock built around one lead asset, track not just sales and guidance but also the gap between revenue and net profit to see whether the thesis really holds.
What TG Therapeutics’ Run Up Already Assumes
TG Therapeutics now trades at US$65.76 after a 124.6% gain from the start of the year. The analyst consensus Narrative on Simply Wall St places its Fair Value above that level, based on expectations around BRIUMVI and an emerging autoimmune portfolio.
Your key question is whether today’s quote already bakes in a broader BRIUMVI franchise and a shift to sustained cash generation that the Narrative argues the market still underestimates.
"The current valuation implies that the market is not fully pricing in the company’s progress toward a roughly $1b annualized BRIUMVI revenue run rate, an expanding autoimmune pipeline, and a shift to a cash-generative model supported by share repurchases."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Before The Next Story Makes Headlines
You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.
- Company 1 - 33% below our estimate - builds electrical and communications projects tied to hyperscale data center construction backlogs.
- Company 2 - 39% below our estimate - advances late stage therapies targeting kidney disease, gene editing, acute pain and endocrinology.
- Company 3 - 32% below our estimate - pursues a bank acquisition and automation platform to deepen higher margin digital lending.
Those are three of them. See all 32 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com